Get the Stockscreener App
34.31
3.25%
1.08
After Hours:
34.41
0.10
+0.29%
Cytokinetics Inc stock is traded at $34.31, with a volume of 2.04M.
It is up +3.25% in the last 24 hours and down -7.30% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$33.23
Open:
$33.39
24h Volume:
2.04M
Relative Volume:
1.35
Market Cap:
$4.11B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-6.5228
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
-5.12%
1M Performance:
-7.30%
6M Performance:
-18.66%
1Y Performance:
-38.93%
1-Day Range:
$33.17
$34.91
1-Week Range:
$32.89
$36.79
52-Week Range:
$29.31
$59.39
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
34.31 | 3.98B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Is Cytokinetics Incorporated stock entering bullish territoryPrice Movement and Market Sentiment Analysis - Newser
Using Ichimoku Cloud for Cytokinetics Incorporated technicalsSafe Momentum Strategy With Trend Analysis - Newser
Citigroup Issues Pessimistic Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - Defense World
Cytokinetics (NASDAQ:CYTK) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Cytokinetics and the Imminent Commercialization of Aficamten: A High-Conviction Buy Before the December 2025 FDA Decision - AInvest
Cytokinetics and the Aficamten Opportunity: Navigating FDA Delays, Strong Analyst Consensus, and High GF Value for a High-Probability Breakout in 2026 - AInvest
Cytokinetics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Pattern recognition hints at Cytokinetics Incorporated upsideTechnical Safety Zone Pattern Recognition - Newser
What candlestick patterns are forming on Cytokinetics IncorporatedFree High Yield Stock Screening Results - Newser
What indicators show strength in Cytokinetics IncorporatedFree Pattern Breakout Entry Stock Forecast - Newser
Cytokinetics 2025 Q2 Earnings Narrowed Losses Amid Revenue Surge - AInvest
Cytokinetics: Citigroup maintains Buy rating, lowers PT to $77 from $80. - AInvest
Cytokinetics shares rise 3.20% after-hours following Q2 2025 earnings call. - AInvest
Cytokinetics, Incorporated shares fall 1.56% intraday after reporting earnings and regulatory updates. - AInvest
CYTK ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Cytokinetics, Incorporated - ACCESS Newswire
Cytokinetics rises as investors await US approval for heart drug - TradingView
Earnings call transcript: Cytokinetics Q2 2025 sees strong revenue beat - Investing.com
Earnings call transcript: Cytokinetics Q2 2025 sees strong revenue beat By Investing.com - Investing.com South Africa
Navigating Financial Challenges Amid Promising Clinical Developments: Cytokinetics Inc. (CYTK) Q2 2025 Earnings Call Highlights - AInvest
Cytokinetics Q2 Loss Narrows, Revenue Rises - MarketScreener
Cytokinetics Q2 2025 Earnings Call Transcript - MarketBeat
Cytokinetics Reports Q2 2025 Financial Results and Updates - TipRanks
Cytokinetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cytokinetics shares rise on strong Q2 results By Investing.com - Investing.com Nigeria
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Cytokinetics: Q2 Earnings Snapshot - San Francisco Chronicle
CYTOKINETICS INC SEC 10-Q Report - TradingView
Cytokinetics Inc earnings beat by $0.30, revenue topped estimates - Investing.com Australia
Cytokinetics Earnings Surge: Revenue Jumps to $66.8M with FDA Decision on Key Drug Coming December - Stock Titan
ATTENTION Cytokinetics, Incorporated Investors: You May Have Been Affected by FraudContact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Federated Hermes Inc. Has $1.37 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
TR | OpenAI4o Initiates Cytokinetics(CYTK.US) With Hold Rating, Announces Target Price $37 - 富途牛牛
Top Executive Sells Thousands in Cytokinetics Stock! - TipRanks
Malik, Cytokinetics EVP, sells $72,680 in shares By Investing.com - Investing.com Canada
Malik, Cytokinetics EVP, sells $72,680 in shares - Investing.com India
Cytokinetics EVP Research & Development Malik Fady Ibraham Buys 2000 Shares at $10.6/Share, Sells 2000 Shares at $36.34/Share. - AInvest
Spinal Muscular Atrophy Market Opportunities and Future Scope - openPR.com
Will Cytokinetics Incorporated Recover After Recent DeclineReliable Investment Entry Signals Confirmed by Charts - beatles.ru
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Purchased by Assetmark Inc. - Defense World
Published on: 2025-08-04 22:46:47 - metal.it
Cytokinetics Incorporated Price Holds Above Key Fib LevelAI Forecast for Trending Stocks Indicates Upside - beatles.ru
Why Cytokinetics Incorporated stock attracts strong analyst attentionSwing Entry Risk Mitigation with Chart Analysis - Newser
What are analysts’ price targets for Cytokinetics Incorporated in the next 12 monthsOutstanding capital growth - Jammu Links News
How strong is Cytokinetics Incorporated company’s balance sheetBuild a diversified portfolio for risk management - Jammu Links News
Cytokinetics Incorporated Stock Analysis and ForecastBuild wealth with long-term growth strategies - Jammu Links News
What makes Cytokinetics Incorporated stock price move sharplyCapitalize on emerging industry trends - Jammu Links News
What is Cytokinetics Incorporated company’s growth strategyMarket-leading capital gains - Jammu Links News
Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Raymond James Financial - MarketBeat
What catalysts could drive Cytokinetics Incorporated stock higher in 2025Build a winning investment portfolio - Jammu Links News
Should I hold or sell Cytokinetics Incorporated stock in 2025Rapid growth opportunities - Jammu Links News
What are the latest earnings results for Cytokinetics IncorporatedExpert Picks Outlook For Beginners - jammulinksnews.com
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.91%
3.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):